BeyondSpring Inc. (BYSI)
NASDAQ: BYSI · Real-Time Price · USD
1.760
+0.040 (2.33%)
At close: Apr 8, 2026, 4:00 PM EDT
1.796
+0.036 (2.05%)
After-hours: Apr 8, 2026, 4:04 PM EDT
BeyondSpring Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
44
Market Cap
72.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 1.35M | - | - |
| Dec 31, 2021 | 1.35M | 1.17M | 650.56% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Alterity Therapeutics | 4.43M |
| Coeptis Therapeutics Holdings | 1.36M |
| MediciNova | 409.66K |
| iBio, Inc. | 300.00K |
| InflaRx | 34.44K |
| Impact BioMedical | 32.00K |
| Fractyl Health | 3.00K |
BYSI News
- 14 days ago - BeyondSpring Files 2025 Annual Report on Form 10-K - GlobeNewsWire
- 2 months ago - BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference - GlobeNewsWire
- 4 months ago - BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path - GlobeNewsWire
- 9 months ago - BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure - GlobeNewsWire
- 11 months ago - BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting - GlobeNewsWire
- 11 months ago - BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 year ago - BeyondSpring Files 2024 Annual Report on Form 10-K - GlobeNewsWire
- 1 year ago - BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies - GlobeNewsWire